EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

GLUT1 as a Potential Therapeutic Target in Glioblastoma

Fnu Ruchika iD, Sanika Suvarnapathaki iD, Antolin Serrano-Farias, Chetan Bettegowda, Jordina Rincon-Torroella iD

Brain Sciences · 28.05.2025 · 15 (6) · 585

DOI: 10.3390/brainsci15060585 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Brain Sciences, online erschienen am 28.05.2025. Verfasst von Fnu Ruchika und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, School of Medicine, Johns Hopkins University, Baltimore, MD 21287, USA. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 88 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glioblastoma (GBM) is the most common primary brain tumor in adults, with a median survival of 15–18 months. GBM cells, like all tumors, exhibit a metabolic shift known as the Warburg effect, favoring glycolysis even under normoxic conditions. GLUT1 is a primary glucose transporter in GBM cells and has been found to be overexpressed in these cells. The acidic microenvironment created by glycolysis facilitates immune evasion, therapy resistance, and tumor growth. Overexpression of GLUT1 is driven by hypoxia-inducible factor-1α (HIF-1α), c-Myc, and other pathways which have been correlated with tumor aggressiveness as well as poor prognosis Recent studies have highlighted the therapeutic potential of targeting GLUT1 in GBM. Preclinical research shows that GLUT1 inhibitors, such as WZB117 and BAY-876, effectively impair tumor metabolism, reduce cell viability, and improve survival in vitro and in animal models. GLUT1 expression also serves as a prognostic marker, with elevated levels linked to poor outcomes. This review highlights the importance of GLUT1 in GBM biology as a potential therapeutic target and biomarker.

Schlagwörter

Stichwörter der Autor:innen

GLUT1Warburg effectglioblastomahypoxia

Autor:innen und Institutionen

  • Department of Neurosurgery, School of Medicine, Johns Hopkins University, Baltimore, MD 21287, USA.

ORCID-Profile: Fnu Ruchika, Sanika Suvarnapathaki, Jordina Rincon-Torroella

Zitieren

APA

Ruchika, F., Suvarnapathaki, S., Serrano-Farias, A., Bettegowda, C., & Rincon-Torroella, J. (2025). GLUT1 as a Potential Therapeutic Target in Glioblastoma. Brain Sciences, 15(6), 585. https://doi.org/10.3390/brainsci15060585

Vancouver

Ruchika F, Suvarnapathaki S, Serrano-Farias A, Bettegowda C, Rincon-Torroella J. GLUT1 as a Potential Therapeutic Target in Glioblastoma. Brain Sciences. 2025;15(6):585. doi:10.3390/brainsci15060585

BibTeX
@article{Ruchika2025,
  author = {Ruchika, Fnu and Suvarnapathaki, Sanika and Serrano-Farias, Antolin and Bettegowda, Chetan and Rincon-Torroella, Jordina},
  title = {GLUT1 as a Potential Therapeutic Target in Glioblastoma},
  journal = {Brain Sciences},
  year = {2025},
  volume = {15},
  number = {6},
  pages = {585},
  doi = {10.3390/brainsci15060585}
}
Kostenlos starten →